TITLE

Sequenom steps toward drug development

AUTHOR(S)
Dorey, Emma
PUB. DATE
July 2001
SOURCE
Nature Biotechnology;Jul2001, Vol. 19 Issue 7, p600
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the multi-million dollar merger of San Diego, California-based genetic analysis firm Sequenom Inc. and Cambridge, England-based clinical genomics company Gemini Genomics PLC on May 29, 2001. Unique features of the deal; Advantages of the deal to Sequenom; Expectations of analysts regarding the deal.
ACCESSION #
8830817

 

Related Articles

  • Differentiation and integration.  // Nature Biotechnology;Jul2001, Vol. 19 Issue 7, p597 

    Editorial. Discusses the merger of biotechnology companies Gemini Genomics PLC and Sequenom Inc. Justification behind the merger of biotechnology companies; Significance of the Gemini and Sequenom merger; Need for integrated collaboration in genomics.

  • Two SNP deals for Gemini. Hodgson, John // Nature Biotechnology;May2000, Vol. 18 Issue 5, p475 

    Reports that at the beginning of April 2000, Great Britain-based Gemini Genomics entered single nucleotide polymorphism-centered collaborations with New Haven, Connecticut-based CuraGen Corp. and San Diego, California and Hamburg, Germany-based Sequenom Inc. Provision of population...

  • breaking news Roundup.  // Chemical Market Reporter;6/4/2001, Vol. 260 Issue 23, p3 

    Presents an update on the chemical industry as of June 4, 2001. Merger of Sequenom Inc. and Gemini Genomics PLC; Move of DuPont Engineering Polymers company to increase the production capacity of Delrin acetal resin at its plant in Dordrecht, Netherlands; Acquisition of the Lumitol acrylic resin...

  • GEMINI DISCOVERS GENE PREDICTOR FOR CONGESTIVE HEART FAILURE.  // Worldwide Biotech;Oct2001, Vol. 13 Issue 10, p5 

    Provides information on the identification of mutations in a gene that may play an important role in the function of human heart muscle, by scientists at Gemini Genomics plc.

  • Sequenom to make offer for Exact, despite a rejection.  // Medical Device Daily;1/15/2009, Vol. 13 Issue 9, p3 

    The article highlights the intention of Sequenom to move forward with an exchange offer to acquire Exact Sciences in an all-stock transaction valued at $41 million, even though Exact reported earlier its board has already rejected an acquisition proposal by Sequenom. Under the proposed deal,...

  • Sequenom to make offer for Exact, despite rejection.  // Diagnostics & Imaging Week;1/22/2009, Vol. 12 Issue 3, p2 

    The article highlights the intention of Sequenom to move forward with an exchange offer to acquire Exact Sciences in an all-stock transaction valued at $41 million, even though Exact reported earlier its board rejected an acquisition proposal by Sequenom. Under the proposed deal, each share of...

  • About SEQUENOM.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p5 

    Provides information on the genetics company SEQUENOM Inc..

  • Sequenom cashes chips. Michael, Adam // Nature Biotechnology;Jun99, Vol. 17 Issue 6, p519 

    Reports that San Diego, California-based company Sequenom Inc. has raised 37 million dollar fund in April 1999 to support the launch of its DNA analysis products. Information about these products to be launched; Increase in share price of the company.

  • Financings Roundup.  // BioWorld Today;9/13/2012, Vol. 23 Issue 178, p7 

    The article reports on the launch of a 110 million dollar private offering of convertible senior notes due in 2017 by Sequenom Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics